Ovid Therapeutics Inc (OVID) Received its Third Buy in a Row

By Austin Angelo

After RBC Capital and Cowen & Co. gave Ovid Therapeutics Inc (NASDAQ: OVID) a Buy rating last month, the company received another Buy, this time from Ladenburg Thalmann & Co. Analyst Michael Higgins maintained a Buy rating on Ovid Therapeutics Inc today and set a price target of $20. The company’s shares closed last Monday at $2.47.

According to TipRanks.com, Higgins is ranked 0 out of 5 stars with an average return of -11.3% and a 32.0% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Armata Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Achieve Life Sciences Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ovid Therapeutics Inc with a $15.33 average price target, which is a 566.5% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.82 and a one-year low of $1.53. Currently, Ovid Therapeutics Inc has an average volume of 299K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.